natgillin/translations-raw huggingface dataset:
The recommended dose is two tablets taken once a day with food for 8, 12 or 24 weeks. 
Priporočeni odmerek sta dve tableti, ki se jemljeta enkrat na dan skupaj s hrano v obdobju 8, 12 ali 24 tednov.
Further information on Viekirax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Viekirax so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This slows the removal of paritaprevir from the body, allowing paritaprevir to act against the virus for longer. 
Tako se upočasni izločanje paritaprevirja iz telesa in paritaprevirju omogoči dlje trajajoče delovanje proti virusu.
The Agency therefore decided that Viekirax's benefits are greater than its risks and it can be authorised for use in the EU. 
Agencija je zato zaključila, da so koristi zdravila Viekirax večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Viekirax? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Viekirax?
It must also not be used together with medicines that can raise or lower the levels of Viekirax's active substances in the blood. 
Prav tako se ne sme uporabljati skupaj z zdravili, ki lahko zvišajo ali znižajo ravni učinkovin zdravila Viekirax v krvi.
Viekirax received a marketing authorisation valid throughout the EU on 15 January 2015. 
Za zdravilo Viekirax je bilo 15. januarja 2015 izdano dovoljenje za promet, veljavno po vsej EU.
Viekirax is available as tablets containing 12.5 mg ombitasvir, 75 mg paritaprevir and 50 mg ritonavir. 
Zdravilo Viekirax je na voljo v obliki tablet, ki vsebujejo 12,5 mg ombitasvirja, 75 mg paritaprevirja in 50 mg ritonavirja.
Almost all the patients with these genotypes treated in studies had the virus cleared from their blood. 
Pri skoraj vseh bolnikih s temi genotipi, zdravljenih v študijah, je bil virus odstranjen iz krvi.
As for all medicines, data on the use of Viekirax are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Viekirax stalno spremljajo.
Other information about Viekirax 
Druge informacije o zdravilu Viekirax
By blocking these proteins, the medicine prevents the hepatitis C virus from multiplying and infecting new cells. 
Z zaviranjem teh beljakovin zdravilo virusu hepatitisa C prepreči, da bi se razmnoževal in okužil nove celice.
What is Viekirax and what is it used for? 
Kaj je zdravilo Viekirax in za kaj se uporablja?
An overview of Viekirax and why it is authorised in the EU 
Pregled zdravila Viekirax in zakaj je odobreno v EU
Side effects reported with Viekirax are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Viekirax, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
The clearance rate was particularly high in patients infected with genotypes 1b and 4. 
Odstranjevanje je bilo še zlasti uspešno pri bolnikih, okuženih z genotipoma 1b in 4.
It contains 3 active substances: ombitasvir, paritaprevir and ritonavir. 
Vsebuje tri učinkovine: ombitasvir, paritaprevir in ritonavir.
What benefits of Viekirax have been shown in studies? 
Kakšne koristi zdravila Viekirax so se pokazale v študijah?
For more information about using Viekirax, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Viekirax glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Why is Viekirax authorised in the EU? 
Zakaj je bilo zdravilo Viekirax odobreno v EU?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Viekirax have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Viekirax upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The combination of medicines used and the duration of treatment will depend on the genotype of hepatitis C virus infecting the patient, the nature of the patient's liver problems, for example if they have liver cirrhosis (scarring) or their liver is not working properly, and whether they have received previous treatment. 
Kombinacija uporabljenih zdravil in trajanje zdravljenja sta odvisna od genotipa virusa hepatitisa C, s katerim je bolnik okužen, od vrste težav z jetri, ki jih ima bolnik, na primer od tega, ali ima cirozo (brazgotinjenje) jeter ali pa njegova jetra ne delujejo pravilno, in od tega, ali je bolnik že bil zdravljen.
The third active substance, ritonavir, does not act directly against hepatitis C virus but it blocks the action of an enzyme called CYP3A that breaks down paritaprevir. 
Tretja učinkovina, ritonavir, ne deluje neposredno proti virusu hepatitisa C, temveč zavira delovanje encima, imenovanega CYP3A, ki razgrajuje paritaprevir.
What are the risks associated with Viekirax? 
Kakšna tveganja so povezana z zdravilom Viekirax?
Viekirax is always used in combination with other medicines for chronic hepatitis C, such as dasabuvir and ribavirin. 
Zdravilo Viekirax se vedno uporablja v kombinaciji z drugimi zdravili za zdravljenje kroničnega hepatitisa C, kot sta dasabuvir in ribavirin.
Several varieties (genotypes) of hepatitis C virus exist, and Viekirax is recommended for patients with virus of genotypes 1a, 1b and 4. 
Obstaja več vrst (genotipov) virusa hepatitisa C, zdravilo Viekirax pa se priporoča za zdravljenje bolnikov z virusom genotipov 1a, 1b in 4.
In 6 initial main studies involving around 2,300 patients infected with hepatitis C virus genotypes 1a or 1b, Viekirax in combination with dasabuvir was effective in clearing the virus from the blood. 
V šestih glavnih študijah, v katere je bilo vključenih približno 2 300 bolnikov, okuženih z genotipoma 1a ali 1b virusa hepatitisa C, je bilo zdravilo Viekirax v kombinaciji z dasabuvirjem učinkovito pri odstranjevanju virusa iz krvi.
Viekirax must not be used in patients with moderate to severe liver impairment and in women taking ethinylestradiol, an oestrogen found in hormonal contraceptives. 
Zdravilo Viekirax se ne sme uporabljati pri bolnikih z zmerno do hudo okvaro jeter in ženskah, ki jemljejo etinilestradiol, tj. vrsto estrogena v hormonskih kontracepcijskih sredstvih.
The 3 active substances in Viekirax work in different ways: ombitasvir blocks the action of a protein in the hepatitis C virus called ‘NS5A' and paritaprevir blocks the action of another protein called ‘NS3/4A', both of which the virus needs to multiply. 
Tri učinkovine v zdravilu Viekirax delujejo na različne načine: ombitasvir zavira delovanje beljakovine v virusu hepatitisa C, imenovane „NS5A“, paritaprevir pa zavira delovanje druge beljakovine, imenovane „NS3/4A“.
Viekirax can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in managing patients with chronic hepatitis C. 
Predpisovanje in izdaja zdravila Viekirax je le na recept, zdravljenje pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s kroničnim hepatitisom C.
Viekirax is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of the liver caused by the hepatitis C virus. 
Zdravilo Viekirax je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi zdravili za zdravljenje odraslih s kroničnim (dolgotrajnim) hepatitisom C, tj. nalezljivo boleznijo jeter, ki jo povzroča virus hepatitisa C.
In a seventh study, patients with liver scarring but stable liver function (compensated cirrhosis) who had genotype 1b infection were treated with Exviera and Viekirax without ribavirin and 100% of patients (60 out of 60 patients) had their blood cleared of the virus. 
V sedmi študiji so bolnike s cirozo jeter in stabilnim delovanjem jeter (kompenzirano cirozo), okužene z genotipom 1b, zdravili z zdraviloma Exviera in Viekirax brez ribavirina in pri 100 % bolnikov (60 od 60) je bil virus odstranjen iz krvi.
The most common side effects with Viekirax in combination with dasabuvir and ribavirin (which may affect more than 1 in 5 people) are tiredness and nausea (feeling sick). 
Najpogostejši neželeni učinki zdravila Viekirax, kadar se uporablja skupaj z dasabuvirjem in ribavirinom (ki se lahko pojavijo pri več kot 1 od 5 bolnikov), so utrujenost in navzea (siljenje na bruhanje).
An additional study showed Viekirax to be effective against genotype 4: when given with ribavirin, Viekirax cleared this genotype from the blood of all the 91 patients infected with it after 12 weeks. 
V dodatni študiji se je zdravilo Viekirax pokazalo kot učinkovito proti genotipu 4, saj je v kombinaciji z ribavirinom po 12 tednih ta genotip odstranilo iz krvi vseh 91 bolnikov, okuženih z njim.
For the full list of side effects and restrictions of Viekirax, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Viekirax glejte navodilo za uporabo.
The European Medicines Agency noted that Viekirax in combination with other medicines is effective in clearing the hepatitis C virus genotypes 1a, 1b and 4, including in patients with liver scarring. 
Evropska agencija za zdravila je ugotovila, da zdravilo Viekirax v kombinaciji z drugimi zdravili učinkovito odstranjuje genotipe 1a, 1b in 4 virusa hepatitisa C iz krvi, tudi pri bolnikih s cirozo jeter.
The company that markets Viekirax will carry out a study in patients who have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Viekirax. 
Podjetje, ki trži zdravilo Viekirax, bo za oceno tveganja ponovitve raka jeter po zdravljenju z neposredno delujočimi protivirusnimi zdravili, kot je zdravilo Viekirax, izvedlo študijo pri bolnikih, ki so preboleli raka jeter.
Although there were some cases of raised liver enzymes in patients treated with Viekirax in combination with dasabuvir and ribavirin, side effects with this combination were generally well tolerated. 
Čeprav je bilo pri bolnikih, zdravljenih z zdravilom Viekirax v kombinaciji z dasabuvirjem in ribavirinom, zabeleženih nekaj primerov zvišanih jetrnih encimov, so bolniki neželene učinke pri tej kombinaciji na splošno dobro prenašali.
In patients with liver scarring, Viekirax treatment in combination with dasabuvir and ribavirin resulted in a clearance rate of between 93% and 100% after 24 weeks of treatment. 
Pri bolnikih s cirozo jeter, ki so prejemali zdravilo Viekirax v kombinaciji z dasabuvirjem in ribavirinom, je bil po 24 tednih zdravljenja virus odstranjen pri 93-100 % bolnikov.
When Viekirax was given with dasabuvir, the virus was cleared from the blood in 91% of the patients. 
V kombinaciji z dasabuvirjem je zdravilo Viekirax virus odstranilo iz krvi pri 91 % bolnikov.
Between 96% and 100% of patients without liver scarring had their blood cleared of the virus after 12 weeks of treatment (with or without ribivarin). 
Pri 96-100 % bolnikov brez ciroze jeter po 12 tednih zdravljenja (brez ribavirina ali v kombinaciji z njim) ni bilo zaznati virusa v krvi.
How is Viekirax used? 
Kako se zdravilo Viekirax uporablja?
How does Viekirax work? 
Kako zdravilo Viekirax deluje?
Final study report expected end of July 2030. 
Končno poročilo o študiji se pričakuje konec julija 2030.
(see section 5.2). 
(Glejte Poglavje 5.2)
In small children, this may be 4 to 6 times a day. 
Pri majhnih otrocih je to lahko 4- do 6-krat na dan.
Talk to your doctor about the best method of contraception for you. 
Pogovorite se z zdravnikom o najboljši kontracepcijski metodi za vas.
If you take these medicines, you may need regular blood tests: 
Če jemljete ta zdravila, boste morda morali opravljati redne krvne teste:
Special populations Elderly (65 years or older) 
Starejši (65 let ali več)
Forty-four patients were evaluated in this analysis. 
V tej analizi je bilo ocenjenih štiriinštirideset bolnikov.
It can be taken in the following ways: 
Lahko se jemlje na naslednje načine:
• reduced number of red blood cells 
• zmanjšano število rdečih krvnih celic
• You will need regular blood tests so your doctor can determine the correct dose for you. 
• Morali boste opravljati redne krvne preiskave, da bo lahko zdravnik določil pravilen odmerek za vas.
Compatibility studies have been conducted (see section 4.5). 
Izvedene so bile študije kompatibilnosti (glejte poglavje 4.5).
Dose adjustment and monitoring in adults and children: 
Prilagoditev in nadzorovanje odmerka pri odraslih in otrocih:
The length of study participation ranged from 0.2 to 5.9 years. 
Sodelovanje v študiji je trajalo od 0,2 do 5,9 let.
There must be at least 3 hours between each dose. 
Med posameznimi odmerki morajo preteči vsaj 3 ure.
The protein binding for PAGN was 7% to 12% and no concentration effects were noted. 
Vezava PAGN na beljakovine je bila med 7 % in 12 %, pri čemer ni bilo opaženih koncentracijskih učinkov.
Development studies 
Razvojne študije
For data regarding pharmacodynamic and pharmacokinetic properties in this age group, see sections 5.1 and 5.2. 
Za podatke glede farmakodinamičnih in farmakokinetičnih lastnosti v tej starostni skupini glejte poglavji 5.1 in 5.2.
Total (N=16) 
(N = 16)
Juvenile animal study 
Študije na mladičih živali
The total daily dose should be divided into equal amounts and given with each meal or feeding (e.g. three times to six times per day). 
Skupni dnevni odmerek je treba razdeliti na enake količine in jih zaužiti ob vsakem obroku ali hranjenju (npr. tri- do šestkrat na dan).
Study 3 was 14 days in duration and Study 4 was 10 days in duration. 
Študija 3 je trajala 14 dni, Študija 4 pa 10 dni.
In other cases the amount of ammonia in the blood goes up quickly. 
V drugih primerih količina amoniaka v krvi naglo naraste.
The following side effects may happen with this medicine: 
Naslednji neželeni učinki se lahko pojavijo pri tem zdravilu:
PAGN is subsequently eliminated in the urine. 
PAGN se nato izloči z urinom.
Each bottle should be discarded after 14 days. 
Vsako steklenico je treba po 14 dneh zavreči.
Frequency is defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Pogostost je opredeljena kot zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
If the volume of your oral syringe is smaller than your prescribed dose, you will have to repeat these steps to get your full dose. 
Če je prostornina vaše peroralne brizge manjša kot je vaš predpisan odmerek, boste morali ponoviti te korake, da boste prejeli polni odmerek zdravila.
The conversion is as follows: 
Pretvorba je naslednja:
Paediatric population Posology is the same for adult and paediatric patients. 
Pediatrična populacija Odmerjanje je enako za odrasle in pediatrične bolnike.
- You must follow this diet carefully. 
- Skrbno se morate držati predpisane diete.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you. 
Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
At the beginning of the treatment, abdominal pain, nausea, diarrhoea, and/or headache may occur; these reactions usually disappear within a few days even if treatment is continued. 
Na začetku zdravljenja se lahko pojavijo bolečine v trebuhu, slabost, driska in/ali glavobol; te reakcije običajno izginejo v nekaj dneh, tudi če se zdravljenje nadaljuje.
• midazolam and barbiturates - used for sedation, trouble sleeping or epilepsy 
• midazolam in barbiturati - uporabljajo se za sedacijo, pri težavah s spanjem ali epilepsiji
Due to the rarity of the UCD population, and the small size of the medicinal product safety population database (N=114), the adverse reaction frequency for rare and very rare is not known. 
Zaradi redkosti populacije z UCD in majhne podatkovne baze o varnosti zdravila v populaciji (N=114) pogostnost redkih in zelo redkih neželenih učinkov ni znana.
This reduces the amount of ammonia in your body. 
Na ta način znižuje količino amoniaka v vašem telesu.
If ammonia is not removed from the body, it can harm the brain and lead to low levels of consciousness or coma. 
Če se amoniak ne odstrani iz telesa, lahko poškoduje možgane in vodi do nizke stopnje zavesti ali kome.
• Your doctor may give you a lower dose if you have kidney or liver problems. 
• Zdravnik vam bo morda predpisal nižji odmerek, če imate težave z jetri ali ledvicami.
There are no data for human fertility. 
Podatkov o vplivu na plodnost pri ljudeh ni.
• decreased or increased appetite, not wanting to eat some foods 
• zmanjšan ali povečan apetit, zavračanje določene hrane
Adjustment based on plasma ammonia 
Prilagoditev na podlagi plazemskega amoniaka
• Your doctor might tell you to take RAVICTI more than 3 times each day. 
• Morda vam bo zdravnik predpisal zdravilo RAVICTI več kot trikrat na dan.
Potential for other medicinal products to affect ammonia Corticosteroids 
Potencial vpliva drugih zdravil na amoniak Kortikosteroidi
Embryo toxicity (increased resorptions) and reduced litter size was also observed. 
Toksičnost za zarodek (povečana resorpcija) in zmanjšanje zaroda sta bila prav tako prisotna.
For additional information regarding method of administration and compatibility/in-use stability studies please refer to section 6.6. 
Za dodatne informacije glede načina odmerjanja in študij kompatibilnosti /stabilnosti med uporabo glejte poglavje 6.6.
• Treatment of acute hyperammonaemia. 
• Zdravljenje akutne hiperamoniemije.
See section 4.8 for how to report adverse reactions. 
Glej poglavje 4.8, kako poročati o neželenih učinkih.
This process allows phenylbutyrate to be absorbed into the circulation. 
Ta proces omogoča, da se fenilbutirat absorbira v obtok.
Young children should be given the medicine during or straight after a feeding. 
Mlajši otroci morajo vzeti zdravilo med hranjenjem ali takoj po njem.
Your doctor will tell you how much RAVICTI you should take each day. 
Zdravnik vam bo povedal, kakšen odmerek zdravila RAVICTI morate vzeti vsak dan.
Spot U-PAGN concentrations below the following levels may indicate improper medicinal product administration and/or lack of compliance: 
Koncentracije U-PAGN pod naslednjimi ravnmi lahko nakazujejo na nepravilno aplikacijo zdravila in/ali pomanjkanje kompliance:
− Note: If possible, use the oral syringe ml size that is nearest to (but not smaller than) the recommended dose (for example, if the dose is 0.8 ml, use a 1 ml oral syringe). 
- Opomba: Če je možno, uporabite velikost peroralne brizge, ki je najbližja priporočenemu odmerku (vendar ne manjša od njega; npr. če je odmerek 0,8 ml, uporabite 1 ml peroralno brizgo).
Each dose should be rounded up to the nearest 0.1 ml for patients less than 2 years of age and 0.5 ml for patients 2 years of age and older. 
Vsak odmerek je treba zaokrožiti navzgor na najbližjih 0,1 ml za bolnike, stare manj kot 2 leti, in 0,5 ml za bolnike, stare 2 leti ali več.
ADRs are summarised in Section 4.8. 
Neželeni učinki so povzeti v poglavju 4.8.
This is because it can pass into breast milk and may harm your baby. 
Zdravilo bi lahko prehajalo v vaše mleko in škodilo vašemu dojenčku.
• This means that ammonia builds up in the body. 
• To pomeni, da se amoniak kopiči v telesu.
Clinical studies in adult patients with UCDs 
Klinične študije pri odraslih z UCD
The bottle should be discarded even if it is not empty. 
Steklenico je treba zavreči, tudi če ni prazna.
• Urea cycle disorders are rare. 
• Motnje ciklusa sečnine so redke.
System Organ Class Preferred Term 
Organski sistem Prednostni izraz
Clinical studies of RAVICTI did not include sufficient numbers of subjects ≥ 65 years of age to determine whether they respond differently than younger subjects. 
Klinične študije zdravila RAVICTI niso vključevale zadostnega števila preiskovancev, starih 65 let ali več, da bi lahko ugotovili, ali se odzivajo drugače kot mlajši preiskovanci.
Uncommon Confusional state, depressed mood 
Stanje zmedenosti, depresivno razpoloženje
Dietary protein is approximately 16% nitrogen by weight. 
Prehranske beljakovine vsebujejo po masi približno 16 % dušika.
• Your daily dose will depend on your size and weight, the amount of protein in your diet, and your overall urea cycle disorder condition. 
• Vaš dnevni odmerek bo odvisen od vaše višine in telesne mase, količine beljakovin v vaši prehrani in vašega splošnega stanja motnje ciklusa sečnine.
RAVICTI helps the body to eliminate waste nitrogen. 
Zdravilo RAVICTI pomaga telesu izločiti odpadni dušik.
Patients should be advised to have a sufficient quantity of syringes on hand. 
Bolniku je treba svetovati, naj ima vedno pri roki zadostno število brizg.
RAVICTI may have major influence on the ability to drive and use machines. 
Zdravilo RAVICTI ima lahko pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
• valproate - a medicine for epilepsy 
• valproat - zdravilo za epilepsijo
Absence of these enzymes or transporters results in the accumulation of toxic levels of ammonia in the blood and brain of affected patients. 
Odsotnost teh encimov ali prenašalcev povzroči kopičenje toksičnih ravni amoniaka v krvi in možganih bolnikov.
A potential effect on CYP2D6 isoenzyme cannot be excluded and caution is advised for patients who receive medicinal products that are CYP2D6 substrates. 
Potencialnega učinka na izoencim CYP2D6 ni možno izključiti in pri bolnikih, ki prejemajo zdravila, ki so substrati CYP2D6, je potrebna previdnost.
EU/1/15/1062/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/15/1062/001
However, the formation of mono- or bis-esters was not studied in humans. 
Vendar pa tvorbe mono- ali bis estrov niso proučevali pri ljudeh.
• contraceptives 
• kontracepcijska sredstva
Each gram of U-PAGN excreted over 24 hours covers waste nitrogen generated from 1.4 grams of dietary protein. 
Vsak gram U-PAGN, ki se izloči v 24 urah, pokrije odpadni dušik, ki nastane iz 1,4 gramov prehranskih beljakovin.
After the first opening of the bottle, the medicinal product must be used within 14 days and the bottle and its contents discarded, even if not empty. 
Po prvem odprtju steklenice je treba zdravilo porabiti v 14 dneh, steklenico in njeno vsebino pa nato zavreči, tudi če ni prazna.
• tests show abnormal ECG (‘electrocardiogram') 
• preiskave, ki kažejo nenormalen EKG (elektrokardiogram)
• existing neurological conditions may get worse 
• težave s pomnjenjem • obstoječe nevrološke težave se lahko poslabšajo
What RAVICTI is and what it is used for 
Kaj je zdravilo RAVICTI in za kaj ga uporabljamo
If you forget a dose, take the missed dose as soon as you remember. 
Če ste pozabili vzeti odmerek zdravila, ga zaužijte takoj, ko se spomnite.
Fertility (number of pregnant rats) was decreased by up to 25%, at a dose of 2.6 times the dose in adult patients. 
Plodnost (število oplojenih podgan) se je zmanjšala do 25 % pri odmerku, ki je bil 2,6-krat večji od odmerka pri odraslih bolnikih.
• If you are a woman who could become pregnant, you must use an effective method of contraception, during treatment with RAVICTI. 
• Če ste ženska v rodni dobi, morate v času zdravljenja z zdravilom RAVICTI uporabljati zanesljivo metodo kontracepcije.
Venous ammonia levels were monitored at a minimum of every 6 months. 
Ravni amoniaka v venski krvi so spremljali vsaj vsakih 6 mesecev.
• Normally, the body turns the extra nitrogen in the protein into a waste compound called ‘ammonia'. 
• Običajno telo spremeni odvečni dušik iz beljakovin v odpadno spojino, ki se imenuje amoniak.
Your doctor will tell you how to take RAVICTI oral liquid. 
Zdravnik vam bo pojasnil, kako jemati peroralno tekočino RAVICTI.
• tests show prothrombin time is longer 
• preiskave, ki kažejo podaljšan protrombinski čas